Efficacy of recombinant bovine basic fibroblast growth factor in treatment of dry eye following phacoemulsification with IOL implantation

Authors: Liu Yuanbin,  Wu Zhonghua,  Guo Jun’er,  Ren Zhifeng,  Duan Huiping,  Sun Xia

DOI: 10.3760/cma.j.issn.2095-0160.2016.02.017
Published 2016-02-10
Cite as Chin J Exp Ophthalmol, 2016,34(2): 175-180.

Abstract

Background

The study on eye surface damage following phacoemulsification with intraocular lens (IOL) implantation is increasingly concerned, and these symptoms were associated with dry eye and often treated by polyethylene glycol eyedrops to remit the discomfortableness. Recombinant bovine basic fibroblast growth factor (rb-bFGF) eyedrops contains neurotrophic factors, but its effect on eye surface damage is worth researching.

Objective

This study was to evaluate the repair effects of rb-bFGF on ocular surface injury after phacoemulsification with IOL implantation.

Methods

A randomized controlled trail was designed. Ninety eyes of 72 consecutive patients with age-related cataract were enrolled in Fenyang Hospital of Shanxi Province from September 2010 to August 2013 under the informed consent. Phacoemulsification with IOL implantation was performed on all the eyes, and tobramycin and dexamethasone eye drops was used for 15 days as basis therapy. According to the treatment sequence, the operative eyes were assigned to rb-bFGF eyedrops group, polyethylene glycol eyedrops group and basis therapy group.rb-bFGF drops and polyethylene glycol drops were topically administered 4 times per day since the first day after surgery for consecutive 30 days in corresponding group, and only basis therapy was maintained in the basis therapy grouply. Corneal fluorescence (FL) staining scores, breakup time of tear film (BUT) and Schirmer Ⅰ test (SⅠt) without topical anesthesia were examined in 1 day before operation and 1 day, 7 days, 15 days and 30 days after operation. The efficacy was intergrouply compared.

Results

No significant differences were seen in the demography and the relevant surface examinational outcomes among the rb-bFGF group, polyethylene glycol drops group and the basis therapy group before surgery (age: F=1.50; gender: χ2=0.336, both at>0.05; FL: F=0.31; BUT: F=0.65; SⅠt: F=0.57; all at P>0.05). Compared with the before operation, FL scores were obviously increased, and BUT values were reduced and SⅠt values were elavated in all the eyes early stage of surgey and then gradually improved with the lapse of postoperative time, showing significant differences (Ftime=7.83, 7.32, 7.17, all at P<0.01). The FL scores, BUT and SⅠt in 15 days after surgery in the rb-bFGF drops group and 30 days after surgery in the polyethylene glycol drops group was closed to those of before surgery (all at P>0.05). However, there were still significant differences between the before and after operation in the basis were closed to those of before surgery therapy group (all at P<0.05). In addition, significant differences were found in corneal FL scores, BUT and SⅠt among these three groups (Fgroup=5.08, 4.15, 4.61, all at P<0.05). In postoperative 15 days and 30 days, the SⅠt values were (12.32±1.18) and (11.32±1.98) mm/5 min, which were significantly lower than (14.36±1.77) and (13.36±2.32) mm/5 min in the polyethylene glycol drops group and (17.25±2.24) and (13.25±2.53) mm/5 min in the basis therapy group (all at P<0.05).

Conclusions

The topical application of rb-bFGF combined with tobramycin and dexamethasone eyedrops can improve the dry eye-related symptoms and promote the repair of the ocular surface injury after phacoemulsification with IOL implantation, and the clinical efficacy of rb-bFGF eyedrops is better than that of polyethylene glycol eyedrops or only tobramycin and dexamethasone eyedrops.

Key words:

[Key words] Dry eye/therapy; Cataract/surgery; Phacoemulsification; Comparative studies; Eyedrops; Recombinant bovine basic fibroblast growth factor; Polyethylene glycol

Contributor Information

Liu Yuanbin
Fenyang College of Shanxi Medical University, Fenyang 032200, China
Wu Zhonghua
Department of Ophthalmology, Fenyang Hospital of Shanxi Province, Fenyang 032200, China
Guo Jun’er
Department of Ophthalmology, Fenyang Hospital of Shanxi Province, Fenyang 032200, China
Ren Zhifeng
Department of Ophthalmology, Fenyang Hospital of Shanxi Province, Fenyang 032200, China
Duan Huiping
Department of Ophthalmology, Fenyang Hospital of Shanxi Province, Fenyang 032200, China
Sun Xia
Fenyang College of Shanxi Medical University, Fenyang 032200, China
(Read 267 times, 1 visits today)
Updated: October 10, 2019 — 3:12 am